IDEAYA Biosciences Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide397 and Trodelvy® Combination in Mtap-Deletion Bladder Cancer
ideaya生物科學宣佈第一例MTAP基因缺失膀胱癌ide397和trodelvy®聯合用藥的1期臨床試驗入組患者
IDEAYA Biosciences Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide397 and Trodelvy® Combination in Mtap-Deletion Bladder Cancer
ideaya生物科學宣佈第一例MTAP基因缺失膀胱癌ide397和trodelvy®聯合用藥的1期臨床試驗入組患者
譯文內容由第三人軟體翻譯。